| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 09/07/2024 | 18:13 | GlobeNewswire Inc. | Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND” | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 09/07/2024 | 15:22 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 09/07/2024 | 15:21 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 09/07/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 15/05/2024 | 22:50 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 15/05/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 14/05/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 01/04/2024 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 28/03/2024 | 13:31 | GlobeNewswire Inc. | ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 04/03/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 22/02/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 24/01/2024 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 17/01/2024 | 00:11 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 05/01/2024 | 22:14 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 20/12/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 12/12/2023 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 21/11/2023 | 14:06 | GlobeNewswire Inc. | ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 08/11/2023 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 06/11/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 03/10/2023 | 15:23 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 29/09/2023 | 18:30 | GlobeNewswire Inc. | ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 27/09/2023 | 23:30 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 22/09/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 21/09/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 19/09/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 14/09/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 25/08/2023 | 22:41 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 07/08/2023 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 03/08/2023 | 22:05 | GlobeNewswire Inc. | ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update | NASDAQ:RSLS | ReShape Lifesciences Inc |
| 29/06/2023 | 14:31 | GlobeNewswire Inc. | ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software | NASDAQ:RSLS | ReShape Lifesciences Inc |